1
|
Cavero-Ibiricu A, Canelas-Fernández J, Gómez-Acebo I, Alonso-Molero J, Martínez-Jiménez D, Llorca J, Cabero-Perez MJ, Dierssen-Sotos T. Association Between Assisted Reproductive Technology and Cerebral Palsy: A Meta-Analysis. Pediatr Neurol 2024; 152:115-124. [PMID: 38244531 DOI: 10.1016/j.pediatrneurol.2023.12.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 10/28/2023] [Accepted: 12/23/2023] [Indexed: 01/22/2024]
Abstract
BACKGROUND Since 1978 many children are born thanks to assisted reproductive technology (ART). However, the long-term effects of these therapies are still not fully known. Our objective is to evaluate the risk of cerebral palsy (CP) after ART compared with that in those spontaneously conceived (SC) and to examine this risk in single, multiple, and preterm births and the evolution of the risk over the years. METHODS PubMed, Embase, and Web of Science databases were searched until December 2022. Studies were included if they studied CP cases in children born through ART. 16 studies were finally selected. Quality of studies was assessed using Newcastle Ottawa Scale. Pooled OR was estimated by weighting individual OR/RR by the inverse of their variance. A random-effect model was applied. To assess the causes of heterogeneity, we performed meta-regression analyses. RESULTS A significantly high risk of CP was found (OR = 1.27; 95% CI 1.12 to 1.43) in children born through ART compared with those SC. This risk increased in singletons (OR = 1.48; 95% CI 1.23 to 1.79) but disappeared in multiple (OR = 1.05; 95% CI 0.93 to 1.18) and preterm births (OR = 1.09; 95% CI 0.87 to 1.37). We found a higher risk of CP in children born before the year 2000 (OR = 3.40; 95% CI 2.49 to 4.63). CONCLUSIONS ARTs slightly increase the risk of CP once the effect of multiple gestation is controlled. Further studies are needed to clarify whether the techniques themselves, fertility problems, or associated maternal comorbidities are responsible for this risk.
Collapse
Affiliation(s)
| | | | - Inés Gómez-Acebo
- Grupo de Medicina Preventiva, Universidad de Cantabria, Santander, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; IDIVAL-Instituto de investigación sanitaria Valdecilla, Santander, Spain
| | - Jessica Alonso-Molero
- Grupo de Medicina Preventiva, Universidad de Cantabria, Santander, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; IDIVAL-Instituto de investigación sanitaria Valdecilla, Santander, Spain.
| | | | - Javier Llorca
- Grupo de Medicina Preventiva, Universidad de Cantabria, Santander, Spain; Retired Professor, Universidad de Cantabria, Santander, Spain
| | - María J Cabero-Perez
- IDIVAL-Instituto de investigación sanitaria Valdecilla, Santander, Spain; Servicio de Pediatría, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Trinidad Dierssen-Sotos
- Grupo de Medicina Preventiva, Universidad de Cantabria, Santander, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; IDIVAL-Instituto de investigación sanitaria Valdecilla, Santander, Spain
| |
Collapse
|
2
|
Sanlés-González I, Grimal-Abejez L, Serrat-Muñoz J, Robert-Boter N, Segura-Egea A, Carreres-Molas A, Alonso-Valle H, Alonso-Molero J, Dierssen-Sotos T, Gómez-Acebo I. Characteristics of patients who died in the hospital emergency service during the SARS-CoV-2 pandemic: a retrospective cohort study in a tertiary hospital in Spain. Intern Emerg Med 2024:10.1007/s11739-023-03519-x. [PMID: 38270773 DOI: 10.1007/s11739-023-03519-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Accepted: 12/17/2023] [Indexed: 01/26/2024]
Abstract
The objective of this study is to analyze the characteristics of patients who died in the Hospital Emergency Department (HED) of a Spanish third-level hospital, with a special focus on those who died due to SARS-CoV-2. A retrospective cohort study was conducted, including all patients over 18 years old who died in the Hospital Emergency Department (HED) of a Spanish third-level hospital located in Badalona, Spain, from Jun 2019 to Dec 2020. Various sociodemographic, clinical, and diagnostic variables of the patients were analyzed to identify potential risk factors associated with mortality. During the first wave of the COVID-19 pandemic, a total of 72 patients died in the HED, representing a 42% increase compared to the pre-pandemic period. Of the deceased patients, 11% were attributed to SARS-CoV-2. Furthermore, it was found that patients who died from SARS-CoV-2 during the first wave were significantly younger than those in the second wave, with an average age of 78.6 ± 3.1 years in the first wave and 91.8 ± 4.8 years in the second wave. No significant differences were found regarding gender or associated comorbidities. Overall, the mortality rate at the HED in relation to COVID-19 was low, and infected patients died at younger ages during the first wave compared to the second wave.
Collapse
Affiliation(s)
| | | | | | - Neus Robert-Boter
- Hospital Universitario Germans Trias I Pujol, 08916, Badalona, Spain
| | | | | | - Héctor Alonso-Valle
- Hospital Universitario Marqués de Valdecilla, 39008, Santander, Cantabria, Spain
| | - Jessica Alonso-Molero
- Facultad de Medicina, Universidad de Cantabria, 39011, Santander, Spain
- IDIVAL Instituto de Investigación Sanitaria Valdecilla, 39011, Santander, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain
| | - Trinidad Dierssen-Sotos
- Facultad de Medicina, Universidad de Cantabria, 39011, Santander, Spain
- IDIVAL Instituto de Investigación Sanitaria Valdecilla, 39011, Santander, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain
| | - Inés Gómez-Acebo
- Facultad de Medicina, Universidad de Cantabria, 39011, Santander, Spain
- IDIVAL Instituto de Investigación Sanitaria Valdecilla, 39011, Santander, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain
| |
Collapse
|
3
|
Alonso-Peña M, Dierssen T, Marin MJ, Alonso-Molero J, Gómez-Acebo I, Santiuste I, Lazarus JV, Sanchez-Juan P, Peralta G, Crespo J, Lopez-Hoyos M. The Cantabria Cohort, a protocol for a population-based cohort in northern Spain. BMC Public Health 2023; 23:2429. [PMID: 38053113 PMCID: PMC10698930 DOI: 10.1186/s12889-023-17318-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Accepted: 11/23/2023] [Indexed: 12/07/2023] Open
Abstract
Cantabria Cohort stems from a research and action initiative lead by researchers from Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital and University of Cantabria, supported by the regional Goverment. Its aim is to identify and follow up a cohort that would provide information to improve the understanding of the etiology and prognosis of different acute and chronic diseases. The Cantabria Cohort will recruit between 40,000-50,000 residents aged 40-69 years at baseline, representing 10-20% of the target population. Currently, more than 30,000 volunteers have been enrolled. All participants will be invited for a re-assessment every three years, while the overall duration is planned for twenty years. The repeated collection of biomaterials combined with broad information from participant questionnaires, medical examinations, actual health system records and other secondary public data sources is a major strength of its design, which will make it possible to address biological pathways of disease development, identify new factors involved in health and disease, design new strategies for disease prevention, and advance precision medicine. It is conceived to allow access to a large number of researchers worldwide to boost collaboration and medical research.
Collapse
Affiliation(s)
| | - Trinidad Dierssen
- Valdecilla Research Institute (IDIVAL), Santander, 39011, Spain
- Faculty of Medicine, University of Cantabria, Santander, 39011, Spain
| | | | - Jessica Alonso-Molero
- Valdecilla Research Institute (IDIVAL), Santander, 39011, Spain
- Faculty of Medicine, University of Cantabria, Santander, 39011, Spain
| | - Inés Gómez-Acebo
- Valdecilla Research Institute (IDIVAL), Santander, 39011, Spain
- Faculty of Medicine, University of Cantabria, Santander, 39011, Spain
| | - Inés Santiuste
- Valdecilla Research Institute (IDIVAL), Santander, 39011, Spain
| | - Jeffrey V Lazarus
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain
- CUNY Graduate School of Public Health and Health Policy (CUNY SPH), New York, NY, USA
| | - Pascual Sanchez-Juan
- CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, 28220, Madrid, Spain
- Alzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII, 28031, Madrid, Spain
| | - Galo Peralta
- Valdecilla Research Institute (IDIVAL), Santander, 39011, Spain
| | - Javier Crespo
- Valdecilla Research Institute (IDIVAL), Santander, 39011, Spain
- Faculty of Medicine, University of Cantabria, Santander, 39011, Spain
- Marques de Valdecilla University Hospital, Santander, 39008, Spain
| | - Marcos Lopez-Hoyos
- Valdecilla Research Institute (IDIVAL), Santander, 39011, Spain
- Faculty of Medicine, University of Cantabria, Santander, 39011, Spain
- Marques de Valdecilla University Hospital, Santander, 39008, Spain
| |
Collapse
|
4
|
Gómez-Acebo I, Llorca J, Alonso-Molero J, Díaz-Martínez M, Pérez-Gómez B, Amiano P, Belmonte T, Molina AJ, Burgui R, Castaño-Vinyals G, Moreno V, Molina-Barceló A, Marcos-Gragera R, Kogevinas M, Pollán M, Dierssen-Sotos T. Circulating miRNAs signature on breast cancer: the MCC-Spain project. Eur J Med Res 2023; 28:480. [PMID: 37925534 PMCID: PMC10625260 DOI: 10.1186/s40001-023-01471-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Accepted: 10/23/2023] [Indexed: 11/06/2023] Open
Abstract
PURPOSE To build models combining circulating microRNAs (miRNAs) able to identify women with breast cancer as well as different types of breast cancer, when comparing with controls without breast cancer. METHOD miRNAs analysis was performed in two phases: screening phase, with a total n = 40 (10 controls and 30 BC cases) analyzed by Next Generation Sequencing, and validation phase, which included 131 controls and 269 cases. For this second phase, the miRNAs were selected combining the screening phase results and a revision of the literature. They were quantified using RT-PCR. Models were built using logistic regression with LASSO penalization. RESULTS The model for all cases included seven miRNAs (miR-423-3p, miR-139-5p, miR-324-5p, miR-1299, miR-101-3p, miR-186-5p and miR-29a-3p); which had an area under the ROC curve of 0.73. The model for cases diagnosed via screening only took in one miRNA (miR-101-3p); the area under the ROC curve was 0.63. The model for disease-free cases in the follow-up had five miRNAs (miR-101-3p, miR-186-5p, miR-423-3p, miR-142-3p and miR-1299) and the area under the ROC curve was 0.73. Finally, the model for cases with active disease in the follow-up contained six miRNAs (miR-101-3p, miR-423-3p, miR-139-5p, miR-1307-3p, miR-331-3p and miR-21-3p) and its area under the ROC curve was 0.82. CONCLUSION We present four models involving eleven miRNAs to differentiate healthy controls from different types of BC cases. Our models scarcely overlap with those previously reported.
Collapse
Affiliation(s)
- Inés Gómez-Acebo
- Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain.
- IDIVAL, Santander, Spain.
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
| | - Javier Llorca
- Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
| | - Jessica Alonso-Molero
- Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain
- IDIVAL, Santander, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
| | - Marta Díaz-Martínez
- Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain
| | - Beatriz Pérez-Gómez
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Pilar Amiano
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Sub Directorate for Public Health and Addictions of Gipuzkoa, Ministry of Health of the Basque Government, San Sebastian, Spain
- Epidemiology of Chronic and Communicable Diseases Group, Biodonostia Health Research Institute, San Sebastián, Spain
| | - Thalía Belmonte
- IUOPA, University of Oviedo and ISPA (Health Research Institute of Asturias), Oviedo, Spain
| | - Antonio J Molina
- Grupo de Investigación en Interacción, Gen-Ambiente-Salud (GIIGAS), Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain
| | - Rosana Burgui
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Institute of Public and Occupational Health of Navarre (ISPLN), 31003, Pamplona, Spain
| | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain
- Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
| | - Víctor Moreno
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Colorectal Cancer Group, ONCOBELL Program, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
- Oncology Data Analytics Program, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
- Department of Clinical Sciences, Faculty of Medicine and health Sciences and Universitat de Barcelona Institute of Complex Systems (UBICS), University of Barcelona, Barcelona, Spain
| | - Ana Molina-Barceló
- Cancer and Public Health UnitFoundation for the Promotion of Health and Biomedical Research (FISABIO-Salud Pública) in the Valencia Region, Valencia, Spain
| | - Rafael Marcos-Gragera
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology (ICO), Girona Biomedical Research Institute (IdiBGi), Girona, Spain
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain
- Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
| | - Marina Pollán
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Trinidad Dierssen-Sotos
- Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain
- IDIVAL, Santander, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
| |
Collapse
|
5
|
Llorca J, Gómez-Acebo I, Alonso-Molero J, Dierssen-Sotos T. Instantaneous reproduction number and epidemic growth rate for predicting COVID-19 waves: the first 2 years of the pandemic in Spain. Front Public Health 2023; 11:1233043. [PMID: 37780431 PMCID: PMC10540620 DOI: 10.3389/fpubh.2023.1233043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Accepted: 08/23/2023] [Indexed: 10/03/2023] Open
Abstract
Introduction Several indicators were employed to manage the COVID-19 pandemic. In this study, our objective was to compare the instantaneous reproductive number and the epidemic growth rate in the Spanish population. Methods Data on daily numbers of cases, admissions into hospitals, admissions into ICUs, and deaths due to COVID-19 in Spain from March 2020 to March 2022 were obtained. The four "pandemic state indicators", which are daily numbers of cases, admissions into hospitals, admissions into ICUs, and deaths due to COVID-19 in Spain from March 2020 to March 2022 were obtained from the Instituto de Salud Carlos III. The epidemic growth rate was estimated as the derivative of the natural logarithm of daily cases with respect to time. Both the reproductive number and the growth rate, as "pandemic trend indicators," were evaluated according to their capacity to anticipate waves as "pandemic state indicators." Results Using both the reproductive number and the epidemic growth rate, we were able to anticipate most COVID-19 waves. In most waves, the more severe the presentation of COVID-19, the more effective the pandemic trend indicators would be. Conclusion Besides daily number of cases or other measures of disease frequency, the epidemic growth rate and the reproductive number have different roles in measuring the trend of an epidemic. Naïve interpretations and the use of any indicator as a unique value to make decisions should be discouraged.
Collapse
Affiliation(s)
- Javier Llorca
- Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
| | - Inés Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Cantabria-Instituto de Investigación Sanitaria de Valdecilla (IDIVAL), Santander, Spain
| | - Jessica Alonso-Molero
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Cantabria-Instituto de Investigación Sanitaria de Valdecilla (IDIVAL), Santander, Spain
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Cantabria-Instituto de Investigación Sanitaria de Valdecilla (IDIVAL), Santander, Spain
| |
Collapse
|
6
|
Palomar-Cros A, Straif K, Romaguera D, Aragonés N, Castaño-Vinyals G, Martin V, Moreno V, Gómez-Acebo I, Guevara M, Aizpurua A, Molina-Barceló A, Jiménez-Moleón JJ, Tardón A, Contreras-Llanes M, Marcos-Gragera R, Huerta JM, Pérez-Gómez B, Espinosa A, Hernández-Segura N, Obón-Santacana M, Alonso-Molero J, Burgui R, Amiano P, Pinto-Carbó M, Olmedo-Requena R, Fernández-Tardón G, Santos-Sánchez V, Fernández de Larrea-Baz N, Fernández-Villa T, Casabonne D, Dierssen-Sotos T, Ardanaz E, Dorronsoro A, Pollán M, Kogevinas M, Lassale C. Consumption of aspartame and other artificial sweeteners and risk of cancer in the Spanish multicase-control study (MCC-Spain). Int J Cancer 2023. [PMID: 37323037 DOI: 10.1002/ijc.34577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Revised: 05/03/2023] [Accepted: 05/04/2023] [Indexed: 06/17/2023]
Abstract
Use of artificial sweeteners (AS) such as aspartame, cyclamate, saccharin and sucralose is widespread. We evaluated the association of use of aspartame and other AS with cancer. In total 1881 colorectal, 1510 breast, 972 prostate and 351 stomach cancer and 109 chronic lymphocytic leukaemia (CLL) cases and 3629 population controls from the Spanish Multicase-Control (MCC-Spain) study were recruited (2008-2013). The consumption of AS, from table-top sweeteners and artificially sweetened beverages, was assessed through a self-administered and validated food frequency questionnaire (FFQ). Sex-specific quartiles among controls were determined to compare moderate consumers (<third quartile) and high consumers (≥ third quartile) vs non consumers (reference category), distinguishing aspartame-containing products and other AS. Unconditional logistic regression models were used to estimate adjusted OR and 95%CI, and results were stratified by diabetes status. Overall, we found no associations between the consumption of aspartame or other AS and cancer. Among participants with diabetes, high consumption of other AS was associated with colorectal cancer (OR = 1.58, 95% CI 1.05-2.41, P trend = .03) and stomach cancer (OR = 2.27 [0.99-5.44], P trend = .06). High consumption of aspartame, was associated with stomach cancer (OR = 2.04 [0.7-5.4], P trend = .05), while a lower risk was observed for breast cancer (OR = 0.28 [0.08-0.83], P trend = .03). In some cancers, the number of cases in participants with diabetes were small and results should be interpreted cautiously. We did not find associations between use of AS and cancer, but found associations between high consumption of aspartame and other AS and different cancer types among participants with diabetes.
Collapse
Affiliation(s)
- Anna Palomar-Cros
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
| | - Kurt Straif
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Boston College, Boston, Massachusetts, USA
| | - Dora Romaguera
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain
- CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Madrid, Spain
| | - Nuria Aragonés
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Public Health Division, Department of Health, Madrid, Spain
| | - Gemma Castaño-Vinyals
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Vicente Martin
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- The Research Group in Gene-Environment and Health Interactions (GIIGAS)/Institute of Biomedicine (IBIOMED), Universidad de León, León, Spain
| | - Victor Moreno
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Cancer Epidemiology Research Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
- Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
- Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - Inés Gómez-Acebo
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Faculty of Medicine, University of Cantabria, Santander, Spain
- IDIVAL-Instituto de investigación sanitaria Valdecilla, Santander, Spain
| | - Marcela Guevara
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Institute of Public and Occupational Health of Navarre (ISPLN), Pamplona, Spain
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Amaia Aizpurua
- Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastian, Spain
- Biodonostia Health Research Institute, Epidemiology of Chronic and Communicable Diseases Group, San Sebastián, Spain
| | - Ana Molina-Barceló
- Cancer and Public Health Research Unit, Foundation for the Promotion of Health and Biomedical Research, (FISABIO-Public Health), Valencia, Spain
| | - José-Juan Jiménez-Moleón
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Instituto de Investigación Biosanitaria ibs.GRANADA, Complejo Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
- Departamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, Spain
| | - Adonina Tardón
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- University of Oviedo, Health Research Institute of Asturias (ISPA), Asturias, Spain
| | - Manuel Contreras-Llanes
- Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain
- Grupo de investigación en Epidemiología Clínica, Ambiental y Transformación Social (EPICAS), Departamento de Sociología, Trabajo Social y Salud Pública, Universidad de Huelva, Huelva, Spain
| | - Rafael Marcos-Gragera
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology (ICO), Girona Biomedical Research Institute (IdiBGi), Girona, Spain
| | - José Mª Huerta
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Department of Epidemiology, Murcia Regional Health Council-IMIB, Murcia, Spain
| | - Beatriz Pérez-Gómez
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Ana Espinosa
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Natalia Hernández-Segura
- The Research Group in Gene-Environment and Health Interactions (GIIGAS)/Institute of Biomedicine (IBIOMED), Universidad de León, León, Spain
| | - Mireia Obón-Santacana
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Cancer Epidemiology Research Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
- Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
- Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - Jessica Alonso-Molero
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Faculty of Medicine, University of Cantabria, Santander, Spain
- IDIVAL-Instituto de investigación sanitaria Valdecilla, Santander, Spain
| | - Rosana Burgui
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Institute of Public and Occupational Health of Navarre (ISPLN), Pamplona, Spain
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Pilar Amiano
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastian, Spain
- Biodonostia Health Research Institute, Epidemiology of Chronic and Communicable Diseases Group, San Sebastián, Spain
| | - Marina Pinto-Carbó
- Cancer and Public Health Research Unit, Foundation for the Promotion of Health and Biomedical Research, (FISABIO-Public Health), Valencia, Spain
| | - Rocio Olmedo-Requena
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Instituto de Investigación Biosanitaria ibs.GRANADA, Complejo Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
- Departamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, Spain
| | - Guillermo Fernández-Tardón
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- University of Oviedo, Health Research Institute of Asturias (ISPA), Asturias, Spain
| | - Vanessa Santos-Sánchez
- Grupo de investigación en Epidemiología Clínica, Ambiental y Transformación Social (EPICAS), Departamento de Sociología, Trabajo Social y Salud Pública, Universidad de Huelva, Huelva, Spain
| | - Nerea Fernández de Larrea-Baz
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Tania Fernández-Villa
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- The Research Group in Gene-Environment and Health Interactions (GIIGAS)/Institute of Biomedicine (IBIOMED), Universidad de León, León, Spain
| | - Delphine Casabonne
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Cancer Epidemiology Research Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
- Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
| | - Trinidad Dierssen-Sotos
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Faculty of Medicine, University of Cantabria, Santander, Spain
- IDIVAL-Instituto de investigación sanitaria Valdecilla, Santander, Spain
| | - Eva Ardanaz
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Institute of Public and Occupational Health of Navarre (ISPLN), Pamplona, Spain
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Ane Dorronsoro
- Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastian, Spain
- Biodonostia Health Research Institute, Epidemiology of Chronic and Communicable Diseases Group, San Sebastián, Spain
| | - Marina Pollán
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Manolis Kogevinas
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Camille Lassale
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Madrid, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| |
Collapse
|
7
|
Gutiérrez-González E, Fernández-Navarro P, Pastor-Barriuso R, García-Pérez J, Castaño-Vinyals G, Martín-Sánchez V, Amiano P, Gómez-Acebo I, Guevara M, Fernández-Tardón G, Salcedo-Bellido I, Moreno V, Pinto-Carbó M, Alguacil J, Marcos-Gragera R, Gómez-Gómez JH, Gómez-Ariza JL, García-Barrera T, Varea-Jiménez E, Núñez O, Espinosa A, Molina de la Torre AJ, Aizpurua-Atxega A, Alonso-Molero J, Ederra-Sanz M, Belmonte T, Aragonés N, Kogevinas M, Pollán M, Pérez-Gómez B. Toenail zinc as a biomarker: Relationship with sources of environmental exposure and with genetic variability in MCC-Spain study. Environ Int 2022; 169:107525. [PMID: 36150295 DOI: 10.1016/j.envint.2022.107525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Revised: 09/08/2022] [Accepted: 09/13/2022] [Indexed: 06/16/2023]
Abstract
BACKGROUND Toenails are commonly used as biomarkers of exposure to zinc (Zn), but there is scarce information about their relationship with sources of exposure to Zn. OBJECTIVES To investigate the main determinants of toenail Zn, including selected sources of environmental exposure to Zn and individual genetic variability in Zn metabolism. METHODS We determined toenail Zn by inductively coupled plasma mass spectrometry in 3,448 general population controls from the MultiCase-Control study MCC-Spain. We assessed dietary and supplement Zn intake using food frequency questionnaires, residential proximity to Zn-emitting industries and residential topsoil Zn levels through interpolation methods. We constructed a polygenic score of genetic variability based on 81 single nucleotide polymorphisms in genes involved in Zn metabolism. Geometric mean ratios of toenail Zn across categories of each determinant were estimated from multivariate linear regression models on log-transformed toenail Zn. RESULTS Geometric mean toenail Zn was 104.1 µg/g in men and 100.3 µg/g in women. Geometric mean toenail Zn levels were 7 % lower (95 % confidence interval 1-13 %) in men older than 69 years and those in the upper tertile of fibre intake, and 9 % higher (3-16 %) in smoking men. Women residing within 3 km from Zn-emitting industries had 4 % higher geometric mean toenail Zn levels (0-9 %). Dietary Zn intake and polygenic score were unrelated to toenail Zn. Overall, the available determinants only explained 9.3 % of toenail Zn variability in men and 4.8 % in women. DISCUSSION Sociodemographic factors, lifestyle, diet, and environmental exposure explained little of the individual variability of toenail Zn in the study population. The available genetic variants related to Zn metabolism were not associated with toenail Zn.
Collapse
Affiliation(s)
- Enrique Gutiérrez-González
- Spanish Agency for Food Safety and Nutrition, Ministry for Consumer Affairs, Alcala 56 St, 28014 Madrid, Spain
| | - Pablo Fernández-Navarro
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029 Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain
| | - Roberto Pastor-Barriuso
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029 Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain
| | - Javier García-Pérez
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029 Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain
| | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain; Barcelona Institute of Global Health (ISGlobal), Carrer del Dr. Aiguader, 88, 08003 Barcelona, Spain; University Pompeu Fabra, Plaça de la Mercè, 10-12, 08002 Barcelona, Spain; Hospital del Mar Medical Research Institute (IMIM), Carrer del Dr. Aiguader, 88, 08003 Barcelona, Spain
| | - Vicente Martín-Sánchez
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain; Institute of Biomedicine (IBIOMED), University of León, Campus Universitario de Vegazana, 24071 León, Spain
| | - Pilar Amiano
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain; Sub-Directorate for Public Health and Addictions of Gipuzkoa, Health Department of the Basque Government, Antso Jakituna Hiribidea, 35, 20010 San Sebastian, Spain; Epidemiology and Public Health Area, Biodonostia Health Research Institute, Paseo Dr. Begiristain, 20014 San Sebastian, Spain
| | - Inés Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain; Department of Medical and Surgical Sciences, Faculty of Medicine, University of Cantabria-IDIVAL, Calle Cardenal Herrera Oria, 39011 Santander, Spain
| | - Marcela Guevara
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain; Public Health Institute of Navarra, C. Leyre, 15, 31003 Pamplona, Navarra, Spain; V, C. de Irunlarrea, 3, 31008 Pamplona, Navarra, Spain
| | - Guillermo Fernández-Tardón
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain; Health Research Institute of Asturias (ISPA), University of Oviedo, Av. del Hospital Universitario, 33011 Oviedo, Spain
| | - Inmaculada Salcedo-Bellido
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain; Department of Preventive Medicine and Public Health, University of Granada, Av. de la Investigación, 11, 18016 Granada, Spain
| | - Victor Moreno
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain; Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Avinguda de la Granvia de l'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain; Colorectal Cancer Group, ONCOBELL Program, Institut de Recerca Biomedica de Bellvitge (IDIBELL), Avinguda de la Granvia de l'Hospitalet, 199, 08908 L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Carrer de Casanova, 143, 08036 Barcelona, Spain
| | - Marina Pinto-Carbó
- Cancer and Public Health Area, The Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Av. de Catalunya, 21, 46020 Valencia, Spain
| | - Juan Alguacil
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain; Centre for Health and Environmental Research, Huelva University, s, Campus El Carmen, Avda. Andalucía, 21071 Huelva, Spain
| | - Rafael Marcos-Gragera
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain; Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology (ICO), IDIBGI, Oncology Coordination Plan, Department of Health Government of Catalonia, Carrer del Dr. Castany, 17190 Girona, Spain; University of Girona, Plaça de Sant Domènec, 3, 17004 Girona, Spain
| | - Jesús Humberto Gómez-Gómez
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain; Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Campus de Ciencias de la Salud, Carretera Buenavista, 30120 El Palmar Murcia, Spain
| | - José Luis Gómez-Ariza
- Department of Chemistry, Faculty of Experimental Sciences, Campus El Carmen, University of Huelva, C/ Menéndez Pelayo, 21002 Huelva, Spain
| | - Tamara García-Barrera
- Department of Chemistry, Faculty of Experimental Sciences, Campus El Carmen, University of Huelva, C/ Menéndez Pelayo, 21002 Huelva, Spain
| | - Elena Varea-Jiménez
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029 Madrid, Spain
| | - Olivier Núñez
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029 Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain
| | - Ana Espinosa
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain; Barcelona Institute of Global Health (ISGlobal), Carrer del Dr. Aiguader, 88, 08003 Barcelona, Spain; University Pompeu Fabra, Plaça de la Mercè, 10-12, 08002 Barcelona, Spain
| | - Antonio J Molina de la Torre
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain; Institute of Biomedicine (IBIOMED), University of León, Campus Universitario de Vegazana, 24071 León, Spain
| | - Amaia Aizpurua-Atxega
- Sub-Directorate for Public Health and Addictions of Gipuzkoa, Health Department of the Basque Government, Antso Jakituna Hiribidea, 35, 20010 San Sebastian, Spain
| | - Jessica Alonso-Molero
- Department of Medical and Surgical Sciences, Faculty of Medicine, University of Cantabria-IDIVAL, Calle Cardenal Herrera Oria, 39011 Santander, Spain
| | - María Ederra-Sanz
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain; Public Health Institute of Navarra, C. Leyre, 15, 31003 Pamplona, Navarra, Spain; V, C. de Irunlarrea, 3, 31008 Pamplona, Navarra, Spain
| | - Thalia Belmonte
- Public Health Department, University of Oviedo, Av. Julián Clavería, 6, 33006 Oviedo, Spain
| | - Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain; Epidemiology Section, Division of Public Health, Department of Health, C. San Martín de Porres, 6, 28035 Madrid, Spain
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain; Barcelona Institute of Global Health (ISGlobal), Carrer del Dr. Aiguader, 88, 08003 Barcelona, Spain; University Pompeu Fabra, Plaça de la Mercè, 10-12, 08002 Barcelona, Spain; Hospital del Mar Medical Research Institute (IMIM), Carrer del Dr. Aiguader, 88, 08003 Barcelona, Spain
| | - Marina Pollán
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029 Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain
| | - Beatriz Pérez-Gómez
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029 Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029 Madrid, Spain.
| |
Collapse
|
8
|
Botella-Juan L, Amezcua-Prieto C, Morales-Suarez-Varela MM, Mateos-Campos R, Ayán-Pérez C, Molina AJ, Ortiz-Moncada R, Redondo-Martín S, Alguacil J, Blázquez-Abellán G, Delgado-Rodríguez M, Alonso-Molero J, Fernández-Villa T. Impact of the COVID-19 Pandemic on the Evolution of Prevalence and Patterns of Cannabis Use among First-Year University Students in Spain-UniHcos Project. Int J Environ Res Public Health 2022; 19:11577. [PMID: 36141846 PMCID: PMC9517240 DOI: 10.3390/ijerph191811577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Revised: 09/06/2022] [Accepted: 09/08/2022] [Indexed: 06/16/2023]
Abstract
Among university students there has been evidence that the COVID-19 pandemic increased their psychological distress, exacerbated by social restrictions. The main objective of this study was to explore the impact of the COVID-19 pandemic on the prevalence and patterns of cannabis use among university students, in contrast to previous trends since 2012. Data from 10,522 first-year university students (73.3% female, Mage 19 (SD = 1.6)) from eleven Spanish universities collected between 2012 and May 2022 was analysed. Prevalences of cannabis use and their differences by sex were studied, as well as changes in patterns of use and its use for coping during the pandemic. It was found that during lockdown, all prevalence rates of cannabis use decreased in both sexes, showing no statistically significant differences and increasing again in the new normal period in both. Among regular cannabis users, 79.7% reported maintaining or increasing their cannabis use during the pandemic, and of these, half reported using cannabis to cope. Moreover, cannabis use in the usual household increased during the lockdown. These results show that although the overall prevalence of cannabis use was reduced during the lockdown, regular users tended to maintain or increase cannabis use. This could imply two different patterns of use among students, one social and occasional versus the other regular, providing new lines of research for prevention and the implementation of social policies.
Collapse
Affiliation(s)
- Lorena Botella-Juan
- Department of Biomedical Sciences, Area of Preventive Medicine and Public Health, Faculty of Health Sciences, University of León, 24071 León, Spain
| | - Carmen Amezcua-Prieto
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública-CIBERESP), 28029 Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Granada, 18016 Granada, Spain
- Instituto de Investigación Biosanitaria (ibs.Granada), 18014 Granada, Spain
| | - María M. Morales-Suarez-Varela
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública-CIBERESP), 28029 Madrid, Spain
- Department of Preventive Medicine and Public Health, Food Sciences, Toxicology and Legal Medicine, University of Valencia, 46100 Burjassot, Spain
| | - Ramona Mateos-Campos
- Area of Preventive Medicine and Public Health, University of Salamanca, 37007 Salamanca, Spain
| | - Carlos Ayán-Pérez
- Well-Move Research Group, Department of Special Didactics, University of Vigo, 36310 Vigo, Spain
| | - Antonio José Molina
- Department of Biomedical Sciences, Area of Preventive Medicine and Public Health, Faculty of Health Sciences, University of León, 24071 León, Spain
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública-CIBERESP), 28029 Madrid, Spain
- The Research Group in Gene-Environment and Health Interactions (GIIGAS), Institute of Biomedicine (IBIOMED), University of León, 24071 León, Spain
| | - Rocío Ortiz-Moncada
- Area of Preventive Medicine and Public Health, Food and Nutrition Research Group, University of Alicante, 03550 Alicante, Spain
| | - Susana Redondo-Martín
- Department of Pathological Anatomy, Microbiology and Preventive Medicine and Public Health, School of Medicine, Universidad de Valladolid, 47005 Valladolid, Spain
- Comisionado Regional para la Droga, Junta de Castilla y León, 47009 Valladolid, Spain
| | - Juan Alguacil
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública-CIBERESP), 28029 Madrid, Spain
- Centre for Research on Natural Resources, Health, and Environment (RENSMA), University of Huelva, 21071 Huelva, Spain
| | - Gemma Blázquez-Abellán
- Department of Medical Sciences, Faculty of Pharmacy, University of Castilla-La Mancha, 02008 Albacete, Spain
| | - Miguel Delgado-Rodríguez
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública-CIBERESP), 28029 Madrid, Spain
- Department of Health Sciences, University of Jaén, 23071 Jaén, Spain
| | - Jessica Alonso-Molero
- Departamento de Medicina Preventiva y Salud Pública, Universidad de Cantabria-IDIVAL, 39008 Santander, Spain
| | - Tania Fernández-Villa
- Department of Biomedical Sciences, Area of Preventive Medicine and Public Health, Faculty of Health Sciences, University of León, 24071 León, Spain
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública-CIBERESP), 28029 Madrid, Spain
- The Research Group in Gene-Environment and Health Interactions (GIIGAS), Institute of Biomedicine (IBIOMED), University of León, 24071 León, Spain
| |
Collapse
|
9
|
Terán AÁ, Palazuelos C, Dierssen-Sotos T, Alonso-Molero J, Llorca J, Gómez-Acebo I. Evolution of Medical Students' Perception of the Patient's Right to Privacy. Int J Environ Res Public Health 2022; 19:11067. [PMID: 36078783 PMCID: PMC9517786 DOI: 10.3390/ijerph191711067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Revised: 08/26/2022] [Accepted: 08/31/2022] [Indexed: 06/15/2023]
Abstract
During clinical rotations, medical students experience situations in which the patients' right to privacy may be violated. The aim of this study is to analyze medical students' perception of clinical situations that affect patients' right to privacy, and to look for the influential factors that may contribute to the infringement on their rights, such as the students' age, sex, academic year or parents' educational level. A cross-sectional study was conducted with a survey via "Google Drive". It consisted of 16 questions about personal information, 24 questions about their experience when rotating and 21 questions about their opinion concerning several situations related to the right to privacy. A total of 129 medical students from various Spanish medical schools participated. Only 31% of 3rd-6th year students declared having signed a confidentiality agreement when starting their clinical practice, and most students (52%) reported that doctors "sometimes", "rarely" or "never" introduce themselves and the students when entering the patients' rooms. Additionally, about 50% of all students reported that they would take a picture of a patient's hospitalization report without his/her (consent), which would be useful for an assignment. Important mistakes during medical students' rotations have been observed, as well as a general lack of knowledge regarding patient's right to privacy among Spanish medical students. Men and older students showed better knowledge of current legislation, as well as those whose parents were both university-educated and those in higher academic years.
Collapse
Affiliation(s)
| | - Camilo Palazuelos
- Faculty of Medicine, Universidad de Cantabria, 39011 Santander, Spain
| | - Trinidad Dierssen-Sotos
- Faculty of Medicine, Universidad de Cantabria, 39011 Santander, Spain
- IDIVAL Instituto de Investigación Sanitaria Valdecilla, 39011 Santander, Spain
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
| | - Jessica Alonso-Molero
- Faculty of Medicine, Universidad de Cantabria, 39011 Santander, Spain
- IDIVAL Instituto de Investigación Sanitaria Valdecilla, 39011 Santander, Spain
| | - Javier Llorca
- Faculty of Medicine, Universidad de Cantabria, 39011 Santander, Spain
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
| | - Inés Gómez-Acebo
- Faculty of Medicine, Universidad de Cantabria, 39011 Santander, Spain
- IDIVAL Instituto de Investigación Sanitaria Valdecilla, 39011 Santander, Spain
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
| |
Collapse
|
10
|
Sánchez-Herrero H, Amezcua-Prieto C, Morales-Suárez-Varela M, Ayán-Pérez C, Mateos-Campos R, Molina AJ, Ortiz-Moncada R, Almaraz-Gómez A, Alguacil J, Delgado-Rodríguez M, Blázquez Abellán G, Alonso-Molero J, Martínez-Ruiz V, Peraita-Costa I, Cancela-Carral JM, Valero-Juan LF, Martín-Peláez S, Fernández-Villa T. [Discrimination and its relationship with risk behaviors and perceived health in spanish university students: a cross-sectional study.]. Rev Esp Salud Publica 2021; 95:e202111156. [PMID: 34779425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Accepted: 08/12/2021] [Indexed: 06/13/2023] Open
Abstract
OBJECTIVE Discrimination during vital moments, such as the university period, can generate a high impact on people's behavior and health. The aim of this study was to analyze the possible association of discrimination with perceived health and with different risk behaviors, as well as to describe gender differences in Spanish university students. Discrimination during vital moments, such as college, can have a high impact on people's behavior and health. METHODS A cross-sectional study was carried out with data from first-year university students from 11 Spanish universities (n=9,862). Discrimination, perceived health, alcohol consumption, smoking, consumption of illegal substances, leisure time connected to the Internet, risky sexual relations, family function, risk of mental health problems and risk of eating disorders were assessed. Prevalences with their 95% confidence intervals were obtained and for quantitative variables the mean and standard deviation were calculated. Odds ratios with 95% confidence intervals were calculated to determine the relationship between discrimination and the other variables. RESULTS An association was found between discrimination and fair or poor perceived health (OR: 1.7; p=0.0001), consumption of illegal substances (OR: 1.3; p=0.002), problematic internet use (OR: 1.3; p=0.004), family dysfunction (OR: 1.8; p=0.0001), risk of mental health problems (OR: 1.9; p=0.0001) and eating disorders (OR: 1.5; p=0.0001). Regarding gender differences, higher prevalence of discrimination was observed in men with health status perceived as fair or worse (OR: 2.2; p=0.0001), family dysfunction (OR: 1.8; p=0.0001), risk of mental health problems (OR: 2.2; p=0.0001) and eating disorders (OR: 1.9; p=0.002). Women, apart from the previous variables, presented association of discrimination with consumption of illegal substances (OR: 1.3; p=0.005) and problematic internet use (OR: 1.4; p=0.002). CONCLUSIONS The study findings underline that there is an association between discrimination and risk behaviors among Spanish university students. In turn, discrimination was associated with poor or fair perceived health, this relationship being similar in both men and women.
Collapse
Affiliation(s)
- Héctor Sánchez-Herrero
- Unidad de Investigación en Cuidados. Hospital Universitario Puerta de Hierro Majadahonda. Madrid. España
- Grupo de Investigación en Enfermería y Cuidados de Salud. Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana. España
| | - Carmen Amezcua-Prieto
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP). Instituto de Salud Carlos III. Madrid. España
- Departamento de Medicina Preventiva y Salud Pública. Universidad de Granada. Granada. España
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA). Granada. España
| | - María Morales-Suárez-Varela
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP). Instituto de Salud Carlos III. Madrid. España
- Área de Medicina Preventiva y Salud Pública. Departamento de Medicina Preventiva y Salud Pública, Ciencias de la Alimentación, Toxicología y Medicina Legal. Facultad de Farmacia. Universitat de Valencia. Valencia. España
| | - Carlos Ayán-Pérez
- Departamento de Didácticas Especiales. Universidad de Vigo. Pontevedra. España
| | - Ramona Mateos-Campos
- Departamento de Ciencias Biomédicas y del Diagnóstico. Área de Medicina Preventiva y Salud Pública. Universidad de Salamanca. Salamanca. España
| | - Antonio José Molina
- Grupo de investigación en interacciones Gen - Ambiente y Salud (GIIGAS). Instituto de Biomedicina (IBIOMED). Universidad de León. León. España
- Departamento de Ciencias Biomédicas. Área de Medicina Preventiva y Salud Pública. Universidad de León. León. España
| | - Rocío Ortiz-Moncada
- Grupo de Investigación en Alimentación y Nutrición (ALINUT). Departamento Enfermería Comunitaria, Medicina Preventiva y Salud Pública e Historia de la Ciencia. Universidad de Alicante. Alicante. España
| | - Ana Almaraz-Gómez
- Departamento de Anatomía Patología, Microbiología, Medicina Preventiva y Salud Pública, Medicina Legal y Forense. Universidad de Valladolid. Valladolid. España
| | - Juan Alguacil
- Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA). Universidad de Huelva. Huelva. España
| | - Miguel Delgado-Rodríguez
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP). Instituto de Salud Carlos III. Madrid. España
- Departamento de Medicina Preventiva y Salud Pública. Universidad de Jaén. Jaén. España
| | - Gemma Blázquez Abellán
- Departamento de Ciencias Médicas. Facultad de Farmacia. Universidad de Castilla-La Mancha. Albacete. España
| | - Jessica Alonso-Molero
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP). Instituto de Salud Carlos III. Madrid. España
- Universidad de Cantabria-Instituto de Investigación Marqués de Valdecilla (IDIVAL). Santander. España
| | - Virginia Martínez-Ruiz
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP). Instituto de Salud Carlos III. Madrid. España
- Departamento de Medicina Preventiva y Salud Pública. Universidad de Granada. Granada. España
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA). Granada. España
| | - Isabel Peraita-Costa
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP). Instituto de Salud Carlos III. Madrid. España
- Área de Medicina Preventiva y Salud Pública. Departamento de Medicina Preventiva y Salud Pública, Ciencias de la Alimentación, Toxicología y Medicina Legal. Facultad de Farmacia. Universitat de Valencia. Valencia. España
| | - José María Cancela-Carral
- Departamento de Didácticas Especiales. Universidad de Vigo. Pontevedra. España
- Grupo de Investigación HealthyFit. Instituto de Investigación Sanitaria Galicia Sur (IIS Galicia Sur). España
| | - Luis Félix Valero-Juan
- Departamento de Ciencias Biomédicas y del Diagnóstico. Área de Medicina Preventiva y Salud Pública. Universidad de Salamanca. Salamanca. España
| | - Sandra Martín-Peláez
- Departamento de Medicina Preventiva y Salud Pública. Universidad de Granada. Granada. España
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA). Granada. España
| | - Tania Fernández-Villa
- Grupo de investigación en interacciones Gen - Ambiente y Salud (GIIGAS). Instituto de Biomedicina (IBIOMED). Universidad de León. León. España
- Departamento de Ciencias Biomédicas. Área de Medicina Preventiva y Salud Pública. Universidad de León. León. España
| |
Collapse
|
11
|
Gómez-Acebo I, Dierssen-Sotos T, Palazuelos-Calderón C, Pérez-Gómez B, Amiano P, Guevara M, Molina AJ, Domingo L, Fernández-Ortiz M, Moreno V, Alguacil J, Fernández-Tardón G, Ibáñez J, Marcos-Gragera R, Diaz-Santos M, Alonso MH, Alonso-Molero J, Castaño-Vinyals G, Palomo AG, Ardanaz E, Molinuevo A, Aragonés N, Kogevinas M, Pollán M, Llorca J. Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study. Breast Cancer Res Treat 2020; 181:667-678. [PMID: 32356254 PMCID: PMC7220874 DOI: 10.1007/s10549-020-05600-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Accepted: 03/18/2020] [Indexed: 12/18/2022]
Abstract
Purpose The objective of this study is to analyse the relative survival with breast cancer in women diagnosed after new treatments were generalised and to ascertain the current effect that tumour characteristics such as grade, stage or subtype have on survival as well as the new AJCC-pathological prognostic score. Methods The breast cancer MCC-Spain follow-up study is a prospective cohort study of 1685 incident breast cancer cases. Women between 20 and 85 years old were recruited between the years 2008 and 2013 in 18 hospitals located in 10 Spanish provinces and they have been followed until 2017/2018. Relative survival was estimated after 3, 5 and 8 years of follow-up using Ederer II method. In addition, Weibull regression adjusted by age, hospital, grade and stage was used to investigate prognosis factors. Results Among components of TNM staging system, tumour size greater than 50 mm (i.e. T3 or T4) more than doubled the risk of dying, while N3 nodal involvement and presence of metastasis had a huge effect on mortality. The AJCC pathological prognostic score strongly correlated with survival; thus, hazard ratios increased as the score rose, being 2.31, 4.00, 4.94, 7.92, 2.26, 14.9 and 58.9 for scores IB, IIA, IIB, IIIA, IIIB, IIIC and IV, respectively. Conclusion Both TNM staging and histological/molecular biomarkers are associated with overall survival in Spanish women with breast cancer; when both are combined in the AJCC pathological prognosis score, the prognostic value improved with risk indices that increased rapidly as the pathological prognosis score increased Electronic supplementary material The online version of this article (10.1007/s10549-020-05600-x) contains supplementary material, which is available to authorised users.
Collapse
Affiliation(s)
- Inés Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain. .,University of Cantabria - IDIVAL, Santander, Spain. .,Facultad de Medicina, Universidad de Cantabria, Avda. Herrera Oria s/n, 39011, Santander, Spain.
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,University of Cantabria - IDIVAL, Santander, Spain
| | | | - Beatriz Pérez-Gómez
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Pilar Amiano
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
| | - Marcela Guevara
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Navarra Public Health Institute, Pamplona, Spain.,IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Antonio J Molina
- Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain
| | - Laia Domingo
- Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim, 25-29, 08003, Barcelona, Spain.,Research Network On Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain
| | | | - Victor Moreno
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Oncology Data Analytics Program, Hospitalet de Llobregat, Catalan Institute of Oncology (ICO), Barcelona, Spain.,Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.,Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - Juan Alguacil
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain
| | - Guillermo Fernández-Tardón
- Instituto de Investigación Sanitaria del Principado de Asturias-ISPA, UNIOVI and CIBERESP, Oviedo, Spain
| | - Josefa Ibáñez
- Cancer and Public Health Area, FISABIO - Public Health, Valencia, Spain.,General Directorate of Public Health, Valencia, Valencian Community, Spain
| | - Rafael Marcos-Gragera
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Epidemiology Unit and Girona Cancer Registry. Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Av. França, s/n, 17007, Girona, Spain.,Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), C/ Dr. Castany, s/n, 17190, Salt, Spain
| | - Marian Diaz-Santos
- Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain
| | - M Henar Alonso
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Oncology Data Analytics Program, Hospitalet de Llobregat, Catalan Institute of Oncology (ICO), Barcelona, Spain.,Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.,Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | | | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,ISGlobal, Barcelona, Spain.,IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | | | - Eva Ardanaz
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Navarra Public Health Institute, Pamplona, Spain.,IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Amaia Molinuevo
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
| | - Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Epidemiology Section, Department of Health, Public Health Division, Madrid, Spain
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,ISGlobal, Barcelona, Spain.,IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Marina Pollán
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Javier Llorca
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,University of Cantabria - IDIVAL, Santander, Spain
| |
Collapse
|
12
|
Dierssen-Sotos T, Gómez-Acebo I, Palazuelos C, Fernández-Navarro P, Altzibar JM, González-Donquiles C, Ardanaz E, Bustamante M, Alonso-Molero J, Vidal C, Bayo-Calero J, Tardón A, Salas D, Marcos-Gragera R, Moreno V, Rodriguez-Cundin P, Castaño-Vinyals G, Ederra M, Vilorio-Marqués L, Amiano P, Pérez-Gómez B, Aragonés N, Kogevinas M, Pollán M, Llorca J. Author Correction: Validating a breast cancer score in Spanish women. The MCC-Spain study. Sci Rep 2020; 10:5980. [PMID: 32238823 PMCID: PMC7113259 DOI: 10.1038/s41598-020-62511-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Collapse
Affiliation(s)
- Trinidad Dierssen-Sotos
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. .,University of Cantabria - IDIVAL, Santander, Spain.
| | - Inés Gómez-Acebo
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,University of Cantabria - IDIVAL, Santander, Spain
| | | | - Pablo Fernández-Navarro
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.,Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain
| | - Jone M Altzibar
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Breast Cancer Screening Programme, Basque Health Department, Osakidetza, Spain
| | - Carmen González-Donquiles
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Grupo de Investigación Interacciones Gen-Ambiente y Salud, Universidad de León, León, Spain
| | - Eva Ardanaz
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Navarra Public Health Institute, Navarra, Spain.,IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Mariona Bustamante
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,ISGlobal Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.,Centre for Genomic Regulation (CRG), the Barcelona Institute of Science and Technology, Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | | | - Carmen Vidal
- Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Juan Bayo-Calero
- Complejo Hospitalario Universitario de Huelva, Centro de Investigación en Salud y Medio Ambiente (CYSMA), Universidad de Huelva, Huelva, Spain
| | - Adonina Tardón
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,IUOPA, Universidad de Oviedo, Asturias, Spain
| | - Dolores Salas
- Valencia Cancer and Public Health Area, FISABIO - Public Health, Valencia, Spain.,General Directorate Public Health, Valencian Community, Valencia, Spain
| | - Rafael Marcos-Gragera
- Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia and Descriptive Epidemiology, Genetics and Cancer Prevention Group [Girona Biomedical Research Institute (IdIBGi)], Catalan Institute of Oncology, Girona, Spain
| | - Víctor Moreno
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.,Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | | | - Gemma Castaño-Vinyals
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,ISGlobal Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain.,IMIM (Hospital Del Mar Medical Research Institute), Barcelona, Spain
| | - María Ederra
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Navarra Public Health Institute, Navarra, Spain.,IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Laura Vilorio-Marqués
- Grupo de Investigación Interacciones Gen-Ambiente y Salud, Universidad de León, León, Spain
| | - Pilar Amiano
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
| | - Beatriz Pérez-Gómez
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.,Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain
| | - Nuria Aragonés
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.,Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain
| | - Manolis Kogevinas
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,ISGlobal Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain.,IMIM (Hospital Del Mar Medical Research Institute), Barcelona, Spain.,School of Public Health, Athens, Greece
| | - Marina Pollán
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.,Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain
| | - Javier Llorca
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,University of Cantabria - IDIVAL, Santander, Spain
| |
Collapse
|
13
|
Alonso-Molero J, Molina AJ, Jiménez-Moleón JJ, Pérez-Gómez B, Martin V, Moreno V, Amiano P, Ardanaz E, de Sanjose S, Salcedo I, Fernandez-Tardon G, Alguacil J, Salas D, Marcos-Gragera R, Chirlaque MD, Aragonés N, Castaño-Vinyals G, Pollán M, Kogevinas M, Llorca J. Cohort profile: the MCC-Spain follow-up on colorectal, breast and prostate cancers: study design and initial results. BMJ Open 2019; 9:e031904. [PMID: 31753885 PMCID: PMC6887054 DOI: 10.1136/bmjopen-2019-031904] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
PURPOSE Since 2016, the multicase-control study in Spain (MCC-Spain) has focused towards the identification of factors associated with cancer prognosis. Inception cohorts of patients with colorectal, breast and prostate cancers were assembled using the incident cases originally recruited. PARTICIPANTS 2140 new cases of colorectal cancer, 1732 of breast cancer and 1112 of prostate cancer were initially recruited in 12 Spanish provinces; all cancers were incident and pathologically confirmed. Follow-up was obtained for 2097 (98%), 1685 (97%) and 1055 (94.9%) patients, respectively. FINDINGS TO DATE Information gathered at recruitment included sociodemographic factors, medical history, lifestyle and environmental exposures. Biological samples were obtained, and 80% of patients were genotyped using a commercial exome array. The follow-up was performed by (1) reviewing medical records; (2) interviewing the patients by phone on quality of life; and (3) verifying vital status and cause of death in the Spanish National Death Index. Ninety-seven per cent of recruited patients were successfully followed up in 2017 or 2018; patient-years of follow-up were 30 914. Most colorectal cancers (52%) were at clinical stage II or lower at recruitment; 819 patients died in the follow-up and the 5-year survival was better for women (74.4%) than men (70.0%). 71% of breast cancers were diagnosed at stages I or II; 206 women with breast cancer died in the follow-up and the 5-year survival was 90.7%. 49% of prostate cancers were diagnosed at stage II and 32% at stage III; 119 patients with prostate cancer died in the follow-up and the 5-year survival was 93.7%. FUTURE PLANS MCC-Spain has built three prospective cohorts on highly frequent cancers across Spain, allowing to investigate socioeconomic, clinical, lifestyle, environmental and genetic variables as putative prognosis factors determining survival of patients of the three cancers and the inter-relationship of these factors.
Collapse
Affiliation(s)
| | - Antonio J Molina
- Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain
| | - Jose Juan Jiménez-Moleón
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain
| | - Beatriz Pérez-Gómez
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
- Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
- Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain
| | - Vicente Martin
- Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
| | - Victor Moreno
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
- Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Spain
- Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - Pilar Amiano
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
| | - Eva Ardanaz
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
- Navarra Public Health Institute, Pamplona, Spain
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Silvia de Sanjose
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
- Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Spain
| | - Inmaculada Salcedo
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain
| | - Guillermo Fernandez-Tardon
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
- Oncology Institute, University of Oviedo, Oviedo, Spain
| | - Juan Alguacil
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
- Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain
| | - Dolores Salas
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
- Área de Cáncer y Salud Pública, FISABIO-Salud Pública, Valencia, Spain
| | - Rafael Marcos-Gragera
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
- Unitat d'Epidemiologia i Registre de Càncer de Girona (UERCG), Pla Director d'Oncologia, Institut Català d'Oncologia, Institut d'Investigaciò Biomèdica de Girona (IdIBGi), Universitat de Girona, Girona, Spain
| | - Maria Dolores Chirlaque
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
- Department of Epidemiology, Regional Health Authority, IMIB-Arrixaca, Murcia University, Murcia, Spain
| | - Nuria Aragonés
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
- Epidemiology Section, Public Health Division, Department of Health, Madrid, Spain
| | - Gemma Castaño-Vinyals
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
- ISGlobal, Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- IMIM (Hospital Del Mar Medical Research Institute), Barcelona, Spain
| | - Marina Pollán
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
- Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
- Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain
| | - Manolis Kogevinas
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
- ISGlobal, Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- IMIM (Hospital Del Mar Medical Research Institute), Barcelona, Spain
| | - Javier Llorca
- University of Cantabria - IDIVAL, Santander, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Granada, Spain
| |
Collapse
|
14
|
Dierssen-Sotos T, Gómez-Acebo I, Palazuelos C, Gracia-Lavedan E, Pérez-Gómez B, Oribe M, Martín V, Guevara M, Rodríguez-Cundín P, Fernández-Tardón G, Marcos-Gragera R, Molina-Barceló A, Díaz-Santos M, Castaño-Vinyals G, Aragonés N, López-Gonzalez A, Amiano P, Castilla J, Alonso-Molero J, Kogevinas M, Pollán M, Llorca J. Fatty acid intake and breast cancer in the Spanish multicase-control study on cancer (MCC-Spain). Eur J Nutr 2019; 59:1171-1179. [PMID: 31069457 DOI: 10.1007/s00394-019-01977-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2018] [Accepted: 04/25/2019] [Indexed: 12/24/2022]
Abstract
PURPOSE To evaluate the association between dietary fat and fat subtype and breast cancer development. METHODS We conducted a case-control study with 1181 cases of incident breast cancer, diagnosed between 2007 and 2012, and 1682 population controls frequency matched (by age, sex, and region) from the Spanish multicenter case-control study MCC-Spain. RESULTS We found a significant protective effect in premenopausal women of total fat intake [OR 0.51 95% CI (0.31-0.86) highest versus lowest tertile], but no effect was observed in menopausal women [OR 1.15 95% CI (0.83-1.60)]. Analyzing by type of fat, this protective effect persisted only for the monounsaturated fatty acids [OR 0.51 95% CI (0.32-0.82)]. In contrast, other fatty acids did not have a significant effect. In addition, a protection against risk of breast cancer was found when polyunsaturated fats were "substituted" by monounsaturated, maintaining the same total fat intake [OR 0.68 95% CI (0.47-0.99)]. Finally, analyzing by breast cancer subtype, we found no effect, except in premenopausal women where intake of moderate [OR 0.52 95% CI (0.33-0.82)] and high monounsaturated fatty acids [OR 0.47 95% CI (0.27-0.82)] maintains a protective effect against ER/PR + tumors. In contrast, in menopausal women, a high intake of monounsaturated fatty acids was associated with higher risk of HER2 + tumors [OR 2.00 95% CI (0.97-4.13)]. CONCLUSION Our study shows a differential effect of monounsaturated fatty acids according to menopausal status and breast cancer subtype.
Collapse
Affiliation(s)
- Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain. .,Facultad de Medicina, Universidad de Cantabria-IDIVAL, Avda. Herrera Oria s/n, 39011, Santander, Spain.
| | - Inés Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,Facultad de Medicina, Universidad de Cantabria-IDIVAL, Avda. Herrera Oria s/n, 39011, Santander, Spain
| | - Camilo Palazuelos
- Facultad de Medicina, Universidad de Cantabria-IDIVAL, Avda. Herrera Oria s/n, 39011, Santander, Spain
| | - Esther Gracia-Lavedan
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,ISGlobal, Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Beatriz Pérez-Gómez
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,Cardiovascular and Metabolic Diseases Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Madalen Oribe
- Public Health Division of Gipuzkoa, Health Department, BioDonostia Research Institute, San Sebastian, Basque Country, Spain
| | - Vicente Martín
- Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain
| | - Marcela Guevara
- Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Spain
| | - Paz Rodríguez-Cundín
- Servicio de Medicina Preventiva, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | | | - Rafael Marcos-Gragera
- Research Group on Statistics, Econometrics and Health (GRECS), Universitat de Girona, Girona, Spain.,Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona, Spain
| | | | - Marian Díaz-Santos
- Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain
| | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,ISGlobal, Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain.,IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Nuria Aragonés
- Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain
| | - Ana López-Gonzalez
- Servicio de Oncología, Complejo Asistencial Universitario de León, León, Spain
| | - Pilar Amiano
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,Public Health Division of Gipuzkoa, Health Department, BioDonostia Research Institute, San Sebastian, Basque Country, Spain
| | - Jesús Castilla
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Spain
| | - Jessica Alonso-Molero
- Facultad de Medicina, Universidad de Cantabria-IDIVAL, Avda. Herrera Oria s/n, 39011, Santander, Spain
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,ISGlobal, Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain.,IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Marina Pollán
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Javier Llorca
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,Facultad de Medicina, Universidad de Cantabria-IDIVAL, Avda. Herrera Oria s/n, 39011, Santander, Spain.,ISGlobal, Barcelona, Spain
| |
Collapse
|
15
|
Gómez-Acebo I, Dierssen-Sotos T, de Pedro M, Pérez-Gómez B, Castaño-Vinyals G, Fernández-Villa T, Palazuelos-Calderón C, Amiano P, Etxeberria J, Benavente Y, Fernández-Tardón G, Salcedo-Bellido I, Capelo R, Peiró R, Marcos-Gragera R, Huerta JM, Tardón A, Barricarte A, Altzibar JM, Alonso-Molero J, Dávila-Batista V, Aragonés N, Pollán M, Kogevinas M, Llorca J. Epidemiology of non-steroidal anti-inflammatory drugs consumption in Spain. The MCC-Spain study. BMC Public Health 2018; 18:1134. [PMID: 30241493 PMCID: PMC6150967 DOI: 10.1186/s12889-018-6019-z] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Accepted: 09/04/2018] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used despite their risk of gastrointestinal bleeding or cardiovascular events. We report the profile of people taking NSAIDs in Spain, and we include demographic factors, health-related behaviours and cardiovascular disease history. METHODS Four thousand sixtyparticipants were selected using a pseudorandom number list from Family Practice lists in 12 Spanish provinces. They completed a face-to-face computerized interview on their NSAID consumption, demographic characteristics, body mass index, alcohol and tobacco consumption and medical history. In addition, participants completed a self-administered food-frequency and alcohol consumption questionnaire. Factors associated with ever and current NSAID consumption were identified by logistic regression. RESULTS Women consumed more non-aspirin NSAIDs (38.8% [36.7-41.0]) than men (22.3 [20.5-24.2]), but men consumed more aspirin (11.7% [10.3-13.2]) than women (5.2% [4.3-6.3]). Consumption of non-aspirin NSAIDs decrease with age from 44.2% (39.4-49.1) in younger than 45 to 21.1% (18.3-24.2) in older than 75, but the age-pattern for aspirin usage was the opposite. Aspirin was reported by about 11% patients, as being twice as used in men (11.7%) than in women (5.2%); its consumption increased with age from 1.7% (< 45 years old) to 12.4% (≥75 years old). Aspirin was strongly associated with the presence of cardiovascular risk factors or established cardiovascular disease, reaching odds ratios of 15.2 (7.4-31.2) in women with acute coronary syndrome, 13.3 (6.2-28.3) in women with strokes and 11.1 (7.8-15.9) in men with acute coronary syndrome. Participants with cardiovascular risk factors or diseases consumed as much non-aspirin NSAID as participants without such conditions. CONCLUSIONS Non-aspirin NSAIDs were more consumed by women and aspirin by men. The age patterns of aspirin and non-aspirin NSAIDs were opposite: the higher the age, the lower the non-aspirin NSAIDs usage and the higher the aspirin consumption. People with cardiovascular risk factors or diseases consumed more aspirin, but they did not decrease their non-aspirin NSAIDs usage.
Collapse
Affiliation(s)
- Inés Gómez-Acebo
- CIBER Epidemiología y Salud Pública, Madrid, Spain.
- Facultad de Medicina, Universidad de Cantabria - IDIVAL, Avda Herrera Oria s/n, 39011, Santander, Spain.
| | - Trinidad Dierssen-Sotos
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Facultad de Medicina, Universidad de Cantabria - IDIVAL, Avda Herrera Oria s/n, 39011, Santander, Spain
| | - María de Pedro
- Facultad de Medicina, Universidad de Cantabria - IDIVAL, Avda Herrera Oria s/n, 39011, Santander, Spain
- Department of Obstetrics and Gynecology, Nuevo Belén University Hospital, Madrid, Spain
| | - Beatriz Pérez-Gómez
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Environmental and Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health (Instituto de Salud Carlos III-ISCIII), Avda. Monforte de Lemos, 5, 28029, Madrid, Spain
- Institute of Health Research "Puerta de Hierro", IDIPHIM, Madrid, Spain
| | - Gemma Castaño-Vinyals
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | | | | | - Pilar Amiano
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
| | - Jaione Etxeberria
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Department of Statistics and O.R., INAMAT, Public University of Navarre, Pamplona, Spain
| | - Yolanda Benavente
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Barcelona, Spain
| | | | | | - Rocío Capelo
- Centro de Investigación en Recursos Naturales, Salud, y Medio Ambiente. (RENSMA), Universidad de Huelva, Huelva, Spain
| | - Rosana Peiró
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Dirección General de Salud Pública, Fundación para el fomento de la investigación sanitaria y biomédica de la Comunidad Valenciana, FISABIO-Salud Pública, Valencia, Spain
| | - Rafael Marcos-Gragera
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Unitat d'Epidemiologia i Registre de Càncer de Girona (UERCG), Pla Director d'Oncologia, Institut Català d'Oncologia, Institut d'Investigaciò Biomèdica de Girona (IdIBGi), Universitat de Girona, Girona, Spain
| | - José M Huerta
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain
| | - Adonina Tardón
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- University of Oviedo, Oviedo, Spain
| | - Aurelio Barricarte
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Navarra Public Health Institute, Pamplona, Spain
- Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
| | - Jone-Miren Altzibar
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Osakidetza-Basque Health Service, BioDonostia Research Institute, Donostia, Spain
| | - Jessica Alonso-Molero
- Facultad de Medicina, Universidad de Cantabria - IDIVAL, Avda Herrera Oria s/n, 39011, Santander, Spain
| | | | - Nuria Aragonés
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Environmental and Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health (Instituto de Salud Carlos III-ISCIII), Avda. Monforte de Lemos, 5, 28029, Madrid, Spain
- Institute of Health Research "Puerta de Hierro", IDIPHIM, Madrid, Spain
- Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain
| | - Marina Pollán
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Environmental and Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health (Instituto de Salud Carlos III-ISCIII), Avda. Monforte de Lemos, 5, 28029, Madrid, Spain
- Institute of Health Research "Puerta de Hierro", IDIPHIM, Madrid, Spain
| | - Manolis Kogevinas
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Javier Llorca
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Facultad de Medicina, Universidad de Cantabria - IDIVAL, Avda Herrera Oria s/n, 39011, Santander, Spain
| |
Collapse
|
16
|
Gonzalez-Donquiles C, Alonso-Molero J, Fernandez-Villa T, Vilorio-Marqués L, Molina AJ, Martín V. The NRF2 transcription factor plays a dual role in colorectal cancer: A systematic review. PLoS One 2017; 12:e0177549. [PMID: 28542357 PMCID: PMC5436741 DOI: 10.1371/journal.pone.0177549] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Accepted: 04/28/2017] [Indexed: 01/15/2023] Open
Abstract
Background Colorectal cancer is one of the most common cancers worldwide, and is influenced by the interplay of various factors, including a very strong genetic component. For instance, incorrect mitochondrial biogenesis is correlated with increased risk of developing colorectal cancer. Thus, it is important to understand the consequences of changes in both the expression and the correct function of the transcription factors that regulate mitochondrial biogenesis, namely NRF2. Objectives The main objective of this paper is to characterise the relationship between NRF2 and colorectal cancer by compiling data from an exhaustive literature search. Methods Information was obtained by defining specific search terms and searching in several databases. After a strict selection procedure, data were tabulated and the relationships between articles were assessed by measuring heterogeneity and by constructing conceptual maps. Results and discussion We found a general consensus in the literature that the presence of oxidizing agents as well as the inhibition of the NRF2 repressor Keap1 maintain NRF2 expression at basal levels. This predominantly exerts a cytoprotective effect on cells and decreases risk of colorectal cancer. However, if NRF2 is inhibited, protection against external agents disappears and risk of colorectal cancer increases. Interestingly, colorectal cancer risk is also increased when NRF2 becomes overexpressed. In this case, the increased risk arises from NRF2-induced inflammation and resistance to chemotherapy. Conclusion The proper basal function of NRF2 and Keap1 are essential for preventing oncogenic processes in the colon. Consequently, any disruption to the expression of these genes can promote the genesis and progression of colon cancer.
Collapse
Affiliation(s)
- C. Gonzalez-Donquiles
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Gene-Environment and Health Research Group, University of Leon, León, Spain
- * E-mail:
| | - J. Alonso-Molero
- Gene-Environment and Health Research Group, University of Leon, León, Spain
| | - T. Fernandez-Villa
- Gene-Environment and Health Research Group, University of Leon, León, Spain
| | - L. Vilorio-Marqués
- Gene-Environment and Health Research Group, University of Leon, León, Spain
| | - A. J. Molina
- Gene-Environment and Health Research Group, University of Leon, León, Spain
| | - V. Martín
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Gene-Environment and Health Research Group, University of Leon, León, Spain
| |
Collapse
|